• Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) receives a bullish price target from Jefferies, suggesting a significant upside.
• The company announces an upsized public offering, aiming to raise capital for further research and development.
• ENTA's stock demonstrates volatility, with a notable trading volume indicating strong investor interest.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) is a clinical-stage biotechnology company that focuses on developing small molecule drugs for virology and immunology. The company is currently in the spotlight due to a recent price target set by Akash Tewari from Jefferies. On October 1, 2025, Tewari set a price target of $20 for ENTA, suggesting a potential increase of approximately 83.74% from its current price of $10.88.

In a strategic move, Enanta has announced an upsized public offering of its common stock. The company is offering 6.5 million shares at $10.00 per share. This offering is expected to close on October 2, 2025, pending customary closing conditions. All shares in this offering are being sold by Enanta itself, which could provide the company with additional capital to further its research and development efforts.

Currently, ENTA is trading at $10.97, reflecting a decrease of approximately 8.35% with a price drop of $1. The stock has shown volatility, with intraday fluctuations between a low of $9.91 and a high of $11.83. Over the past year, ENTA has experienced a high of $15.34 and a low of $4.09, indicating significant price movement and investor interest.

Enanta's market capitalization is approximately $234.5 million, with a trading volume of 2,459,054 shares. This level of trading activity suggests that investors are closely watching the company's developments, especially in light of the recent public offering and the price target set by Jefferies. The additional capital from the stock offering could potentially support Enanta's growth and innovation in the biotechnology sector.